Syneos Health And Optum Target Clinical Trial Planning With New Partnership
By Elizabeth Urbanek, Executive Editor
Syneos Health and Optum are partnering to help sponsors make better decisions during clinical development, with a focus on testing trial scenarios, evaluating protocol assumptions and identifying potential risks before they affect execution.
Announced Oct. 20, the collaboration brings together Optum’s healthcare expertise and artificial intelligence (AI) resources with Syneos Health’s clinical development and trial operations capabilities. The companies plan to focus on adaptive development planning, patient and site access, and the data and technology needed to support those efforts. Syneos Health will also serve as Optum’s preferred partner for developing its site management organization.
“Clinical research is one of the most complex and data-intensive activities in healthcare, yet necessary connections are fragmented all too often,” said Sandeep Dadlani, CEO of Optum Insight, in the partnership announcement. “Our collaboration with Optum brings deep healthcare expertise that can help improve trial design and implementation with greater precision and predictability.”
For clinical supply, the planning piece is worth a closer look. A change to a study can affect product requirements, but supply teams need time to work through what that change means for manufacturing, packaging, labeling and distribution.
What This Means For Clinical Supply
A sponsor may decide to expand enrollment, add a treatment arm, or change a protocol. The clinical team needs to understand how this will impact the study while supply teams need to decide how much additional product will be needed, when it must be available, and whether the existing plan can support the change.
That can get complicated quickly. Manufacturing capacity may already be committed. Comparator product may take months to source. Packaging and labeling may be scheduled around the current protocol, and inventory already in distribution may not be where the study needs it next.
Site activation brings its own challenges. Changing the order in which countries or sites open can shift demand, while import requirements and shipping lead times limit how quickly product can be moved. A change that looks straightforward from a development perspective may require several adjustments to the supply plan.
This is where scenario planning could help. If teams can work through the supply implications before a decision is finalized, they have a better chance of identifying constraints while there is still time to respond. That might mean adjusting packaging schedules, reviewing inventory allocation or determining whether additional product can be manufactured and released in time.
The key is getting clinical supply involved early enough to contribute to the decision, rather than asking the team to make the new plan work after the fact.
Syneos Health and Optum have not yet detailed how clinical supply will fit into the partnership’s model or when the capabilities will be implemented. For now, the announcement points to a broader effort to improve how clinical development decisions are made. How that translates into day-to-day supply planning remains to be seen.
The Supply Question
When a protocol, enrollment forecast or site activation plan changes, does clinical supply have enough visibility and time to adjust the plan before product availability becomes a problem?
Related Clinical Supply Leader Editorials
- Three Months Too Late: How Late Decisions Create Clinical Supply Challenges
- The Hidden Work Between Protocol And Execution: Translating Requirements Into Supply Strategy
- Why Shelf Life Should Shape Global Country Activation
About The Author:
Elizabeth Urbanek is the Executive Editor for Clinical Supply Leader, where she works with clinical trial supply and logistics professionals across pharma and biotech to bring real-world perspectives, operational challenges, trends, scientific insights and regulatory strategy to the field.
Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.
Elizabeth is passionate about connecting people and ideas, identifying emerging themes and showcasing work that can move the clinical supply field forward.